Roche Proves Again Why It Will Likely Rout Shire's Hemophilia Business

Roche (RHHBY) jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire (SHPG) to slip.

X

Analysts expect Roche to rout Shire with its hemophilia treatment. Blood disease treatments are among Shire's biggest moneymakers. But it's unlikely Shire stock will move much on the news, RBC analyst Douglas Miehm said in a report.

"We view downside as relatively limited for Shire given the pending Takeda (Pharmaceutical's) acquisition and

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

RHHBY [+]    Monday [+]    Hemlibra [+]    Shire [+]    SHPG [+]    Analysts [+]    RBC [+]    Douglas Miehm [+]    Takeda [+]    Pharmaceutical [+]   

More #news: